Unmasking unugyada unugyada kansarka

Iyadoo unugyada kansarku ay horumarayaan, waxay ku ururaan boqollaal isbeddello hidde ah iyo kuwa epigenetic ah, taas oo dhalisay qiyaasaha borotiinka ee borotiinka taas oo ka duwan midka unugyada caafimaadka qaba. Hase yeeshe, inkastoo ay maskaxdooda isku dhafan yihiin, unugyada kansarku waxay ka baxaan aqoonsiga iyo weerarka habka difaaca jirka.

Immunotherapies, gaar ahaan koontaroolka kumbuyuutarrada ee dib u soo kabashada unugyada T-da, ayaa is-beddelay daaweynta noocyada kansarka qaarkood. Daawooyinkan xoojinta ah ayaa waxay keeneen sicir-celin aan wax ku-ool ah loogu talagalay bukaannada qaarkood. Nasiib darro, kansarrada intooda badani waxay ku fashileen inay ka jawaabaan cudurrada difaaca jirka iyo istiraatiijiyooyinka cusub.

Koox bayoolajiga kansarka ka mid yihiin xubno ka mid ah shaybaarada ee David H. Koch Professor of Biology Tyler godadka, oo ah agaasimaha machadka Koch ee Cancer Research dhamaystiran at MIT iyo xubin kale ah Koch Institute Forest White, Ned iyo Janet C. Bemis Professor Rice iyo xubin ka mid ah Xarunta MIT ee Cancer Medicine qiray, qaateen hab dhamaystiraya hagaajinaysa habka difaaca jirka.

Inkasta oo unugyada kansarku ay badanaa la xidhiidha borotiinka mutate-yada, borotiinnadaas waxay ka muuqdaan dusha qolka, halkaas oo lagu aqoonsan karo unugyada difaaca. Cilmi-baarayaasha ayaa soo jiidanaya fasal fiican oo lagu daaweeyay daawooyinka ladagaallanka kansarka, 90 kuleyliyaha kuleylka (HSP90), taasoo abuuraysa unugyada kansarku si sahlan loo ogaado iyaga oo muujinaya borotiinka mutateeska ah.

Badanaa HSP90 inhibitor ah ayaa si ba'an loogu baaray daaweynta kansarka. HSP90 wuxuu door ka qaataa xasilinta qaabka borotiinka oo ay hoos u dhigtay isbeddellada qumman. Si kastaba ha ahaatee, inkastoo ay jiraan caddaymo balaadhan oo hor leh, HSP90 inhibitorayaasha waxay soo saareen natiijooyin niyadjabsan oo ku jira tijaabooyinka kiliinikada, oo cidna ma aysan helin ansixinta FDA.

In a waxbarasho muuqata Cilmi baarista kansarkaCilmi baadhayaashu waxay cadeeyeen sababo ka imanaya natiijooyinka niyadjabsan. Kufsiyeyaasha HSP90 kaliya ayaa lagu baaray qiyaasta daawada bolus - qiyaaso, qiyaaso waaweyn - taasoo badanaa keenta saameynta aan loo baahnayn ee bukaanka.

RNA qoondaynta xarumaha bukaan-socodka bini-aadannimada iyo kansarka ayaa muujiyay in jadwal-daweynta buug-qaadashadu ay natiijooyinka ka soo baxeen tirtirka borotokoolka 1 (HSF1). Ma aha oo keliya HSF1 waxay u hawlgelisaa jawaabta jawaabta kulka ee unugyada kulaylka, taas oo ka hortageysa saameynta HSP90 inhibitor, laakiin waxaa la ogyahay in uu yahay awood suurto gal ah oo ah kansarka unugyada kansarka.

Marka la eego farqiga, cilmi-baarayaashu waxay isticmaalaan kansar leh nidaam difaaca oo joogto ah si ay u muujiyaan in daaweynta HSP90 ee joojiya heerkoodu yar yahay labaduba ay dhaliyeen jawaab-celinta kulka kulaylka iyo difaaca jirka ee la xidhiidha qadar sare.

Iyadoo la adeegsanayo habka ay sameysay sheybaarka cad (White Lab) ee isku dhafay maadada 'proteomics' iyo 'modeling computations', ayaa cilmi baarayaashu ogaadeen in nidaamka cusub ee daaweynta uu kordhiyay tirada iyo kala duwanaanta peptides (jajabyada borotiinka) ee dusha jirka. Peptides kuwaas oo kooxdu ay ogaadeen in la sii daayo HSP90 inta lagu jiro mudada yar ee la joojiyay, ka dibna waxaa la qaaday mishiinnada antigen-soo bandhigaya oo loo isticmaalo in lagu calaamadeeyo unugyada difaaca jirka.

"Natiijooyinkaasi waxay ku xidhmaan a dhinacyo Fundamental of biology cell - laabanto protein - in jawaabaha difaaca anti-buro" ayuu yidhi qoraaga hogaanka Alex Jaeger, walaalahooda ah postdoctoral shaybaarka godadka iyo foomka xubin ka mid ah shaybaarka ee nin cilmiga nafleyda barta MIT daahay iyo Professor Susan Lindquist , Yaa leh shaqada u waxyoonay waxbarasho ee kacmaha HSP90 scheule. "Waxaan rajeynayaa, Waxyaabihii our kulaku kartaa xiisaha Iscelin HSP90 sida hab kaabaha for immunotherapy."

Iyadoo la adeegsanayo habka cusub ee daaweynta, cilmi-baarayaashu waxay muujiyeen in ay awoodaan in ay yareeyaan daawada diirada ee heerarka kuwaas oo ah 25-50 waqtiyo ka hooseeya kuwa loo isticmaalo tijaabooyinka bukaan socodka. Muhiimadda, sababta oo ah noocyo badan oo HSP90 inhibitor ah ayaa mar hore loo sameeyay baaritaan caafimaad oo ballaadhan, nidaamka cusub ee daaweynta ayaa si dhakhso ah loogu baadhi karaa bukaanada.

Shaqadan waxaa taageertay Ururka Cilmi-baarista Kansarka ee Damon Runyon Cancer, Khasaarada Cilmi-baarista Imeda ee Immune Oncology, iyo Deeqda Tababarka MIT ee Sayniska Deegaanka; shaqada aasaasiga ah ee HSF1 waxaa taageeray Barnaamijka Cilmi Baarista ee Koch Institute.

Maqaalkani wuxuu u muuqday midka hore http://news.mit.edu/2019/unmasking-mutant-cancer-cells-0717